Nyxoah מספקת עדכון על הנוכחות המורחבת במזרח התיכון
מונט-סנט-גיברט, בלגיה, 23 בספטמבר 2025, (GLOBE NEWSWIRE) :
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH) ("Nyxoah" או "החברה"), חברת טכנולוגיות רפואיות שמתמקדת בפיתוח ומסחור של פתרונות ושירותים חדשניים לדום נשימה חסימתי בשינה (OSA), הודיעה היום על המשך הרחבת טביעת הרגל המסחרית שלה במזרח התיכון, לאחר השתלת Genio® המוצלח הראשון באבו דאבי בספטמבר 2025.
Nyxoah Provides an Update on Expanded Middle East Presence
New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025
Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET, GLOBE NEWSWIRE:
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced the continued expansion of its commercial footprint in the Middle East, following the first successful Genio® implant in Abu Dhabi in September 2025.
The Middle East is home to world-class healthcare systems, renowned Key Opinion Leaders, and centers of excellence with outstanding facilities. Nyxoah is proud to partner with these institutions spread over Dubai, Kuwait, and Abu Dhabi to broaden access to Genio and improve outcomes for patients living with Obstructive Sleep Apnea who are unable to tolerate CPAP.
Olivier Taelman, Chief Executive Officer of Nyxoah, commented: "The Middle East represents an important and growing market for Nyxoah, and we are delighted to see this momentum since our initial launch in the region earlier this year. Expanding from Dubai into Kuwait and Abu Dhabi allows us to bring the unique, patient-centric Genio solution to more individuals suffering from Obstructive Sleep Apnea. We are grateful to collaborate with leading healthcare institutions and experts in the region, who share our mission to transform the treatment of OSA and make sleep simple for patients worldwide."
With its growing network of centers across the Middle East, Nyxoah continues to deliver on its commitment to expand patient access to Genio, the only leadless, externally powered bilateral hypoglossal nerve stimulation system for the treatment of moderate-to-severe OSA.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device..
Contact:
Nyxoah John Landry, CFO [email protected]
Attachment
*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire
חיים נוי, עיתונאי, עורך ראשי של סוכנות החדשות הבינ"ל IPA, לשעבר עורך ראשי של סוכנות הידיעות עתים, חבר תא מבקרי התיאטרון באגודת העיתונאים